Utilization patterns of glucagon like Peptide-1 receptor agonists prior to bariatric and metabolic surgery: a multicenter study

Keyphrases

• Utilization Pattern 100%
• Bariatric Surgery 100%
• Metabolic Surgery 100%
• Glucagon-like peptide-1 Receptor (GLP-1R) 100%
• Receptor Agonist 90%
• A1 Receptor 90%
• Glucagon-like 90%
• Bariatric Patients 50%
• Weight Loss 40%
• Adverse Events 20%
• Liraglutide 20%
• Semaglutide 20%
• Israel 10%
• Adverse Effects 10%
• Treatment Outcome 10%
• Inappropriate Use 10%
• Obesity Management 10%
• Surgery Department 10%
• Demographic Data 10%
• Clinical Data 10%
• Type 2 Diabetes Mellitus (T2DM) 10%
• Young Age 10%
• Dyslipidemia 10%
• Overweight or Obesity 10%
• Duration of Use 10%
• Recommended Dose 10%
• Prevalence Characteristics 10%
• Maximal Weights 10%
• Agonist Treatment 10%
• Excess Weight Loss 10%
• Event Outcomes 10%
• Treatment Information 10%
• History of Surgery 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Glucagon Like Peptide 1 Receptor Agonist 100%
• Adverse Event 20%
• Liraglutide 20%
• Semaglutide 20%
• Prevalence 10%
• Dyslipidemia 10%
• Maturity Onset Diabetes of the Young 10%

Medicine and Dentistry

• Treatment Outcome 10%